PhytoHealth (4108) reported revenue of NT$13.7 million for Oct 2026, +6.0% year on year and +15.3% from the previous month. Revenue for Jan–Oct 2026 was NT$120.5 million (+5.4% year on year).
In Oct 2026, it ranked No. 129 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$13.7 million | +6.0% | +15.3% |
| Sep 2026 | NT$11.9 million | -31.8% | -6.5% |
| Aug 2026 | NT$12.7 million | +25.8% | +6.6% |
| Jul 2026 | NT$11.9 million | -4.1% | -16.7% |
| Jun 2026 | NT$14.3 million | +27.8% | +20.3% |
| May 2026 | NT$11.9 million | +18.5% | +21.7% |
| Apr 2026 | NT$9.8 million | -0.8% | -1.0% |
| Mar 2026 | NT$9.9 million | -21.4% | +6.9% |
| Feb 2026 | NT$9.2 million | +5.0% | -40.2% |
| Jan 2026 | NT$15.4 million | +67.6% | +79.5% |
| Dec 2025 | NT$8.6 million | -38.5% | -26.2% |
| Nov 2025 | NT$11.6 million | -14.1% | -9.7% |
| Oct 2025 | NT$12.9 million | +35.9% | -25.8% |
| Sep 2025 | NT$17.4 million | +10.9% | +72.7% |
| Aug 2025 | NT$10.1 million | -3.8% | -18.8% |
| Jul 2025 | NT$12.4 million | -9.2% | +10.9% |
| Jun 2025 | NT$11.2 million | -35.8% | +11.5% |
| May 2025 | NT$10 million | -40.1% | +1.9% |
| Apr 2025 | NT$9.8 million | -1.5% | -21.6% |
| Mar 2025 | NT$12.5 million | +24.8% | +42.8% |
| Feb 2025 | NT$8.8 million | -9.8% | -4.6% |
| Jan 2025 | NT$9.2 million | -28.0% | -34.2% |
| Dec 2024 | NT$14 million | -21.6% | +3.2% |
| Nov 2024 | NT$13.6 million | +7.3% | +42.8% |
| Oct 2024 | NT$9.5 million | -41.2% | -39.5% |
Jan–Oct 2026 cumulative: NT$120.5 million (+5.4% YoY)
Other Biotech & Medical companies
Compare with peers: PhytoHealth vs PEC / PhytoHealth vs Lotus Pharm / PhytoHealth vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16